Skip Navigation

A Phase I, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft), with Single-Agent Graft-Versus-Host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03802695

Study #:
STUDY00144665

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03802695

View Complete Trial Details & Eligibility at ClinicalTrials.gov